Quiver Biotech Profile
Key Indicators
- Authorised Capital ₹ 3.75 Cr
as on 24-10-2024
- Paid Up Capital ₹ 3.48 Cr
as on 24-10-2024
- Company Age 15 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.24 Cr
as on 24-10-2024
- Satisfied Charges ₹ 6.20 M
as on 24-10-2024
- Revenue 20.35%
(FY 2023)
- Profit -9.32%
(FY 2023)
- Ebitda 3.28%
(FY 2023)
- Net Worth 3.78%
(FY 2023)
- Total Assets 31.22%
(FY 2023)
About Quiver Biotech
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.75 Cr and a paid-up capital of Rs 3.48 Cr.
The company currently has active open charges totaling ₹2.24 Cr. The company has closed loans amounting to ₹6.20 M, as per Ministry of Corporate Affairs (MCA) records.
Bramhananda Iragamreddy and Sunitha Iragamreddy serve as directors at the Company.
- CIN/LLPIN
U24100TG2009PTC062978
- Company No.
062978
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Mar 2009
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Rangareddy, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Quiver Biotech?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bramhananda Iragamreddy  | Director | 06-Mar-2009 | Current |
| Sunitha Iragamreddy | Director | 06-Mar-2009 | Current |
Financial Performance of Quiver Biotech.
Quiver Biotech Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 20.35% increase. The company also saw a slight decrease in profitability, with a 9.32% decrease in profit. The company's net worth moved up by a moderate rise of 3.78%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Quiver Biotech?
In 2023, Quiver Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Quiver Life Sciences Private LimitedActive 19 years 10 monthsBramhananda Iragamreddy and Sunitha Iragamreddy are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 06 Dec 2014 | ₹2.24 Cr | Open |
Ing Vysya Bank Limited Creation Date: 29 Nov 2014 | ₹6.20 M | Satisfied |
How Many Employees Work at Quiver Biotech?
Quiver Biotech has a workforce of 39 employees as of Mar 27, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Quiver Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Quiver Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
